@article{babd89763ba3485da2ab2ce70fb0ed04,
title = "Targeting AMPA and kainate receptors in neurological disease: Therapies on the horizon?",
author = "Swanson, {Geoffrey T.}",
note = "Funding Information: Dr Conn has received compensation over the past 2 years as a consultant from Merck and Co, Johnson and Johnson, Hoffman La Roche, GlaxoSmithKline, Lundbeck Research USA, Epix Pharmaceuticals, Invitrogen Life Technologies, Evotec Inc., Addex Pharmaceuticals, Michael J Fox Foundation, Seaside Therapeutics, Cephalon Inc., AstraZeneca USA, NeurOp Inc., Forest Research Institute, LEK Consulting, The Frankel Group, Prestwick Chemical Co, Millipore Corp., Genentech, IMS Health, Primary Insight, and Otsuka. Dr Conn has received honoraria as a speaker from University of Toronto, American Society for Bone and Mineral Research, University of Alabama Birmingham, University of Michigan, Southern Research Institute, Harvard Medical School, and the University of North Carolina. Dr Conn receives research support that includes salary support from NIH, Michael J Fox Foundation, Seaside Therapeutics, and Vanderbilt University. ..................................................................... Galici R, Echemendia NG, Rodriguez AL, Conn PJ (2005). A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J Pharmacol Exp Ther 315: 1181–1187. Galici R, Jones CK, Hemstapat K, Nong Y, Eche-mendia NG, Williams LC et al (2006). Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic-and anxiolytic-like effects in mice. J Pharmacol Exp Ther 318: 173–185.",
year = "2009",
month = jan,
doi = "10.1038/npp.2008.158",
language = "English (US)",
volume = "34",
pages = "249--250",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "1",
}
